Join to View Full Profile
6560 Fannin StreetSuite 802Houston, TX 77030
Phone+1 713-363-7310
Fax+1 713-790-2059
Dr. Thonhoff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jason Thonhoff is a neurologist in Houston, TX and is affiliated with Houston Methodist Hospital. He received his medical degree from the University of Texas Medical Branch and has been in practice 9 years. He specializes in neuromuscular medicine and is experienced in amyotrophic lateral sclerosis and muscular dystrophy. He has more than 20 publications and over 500 citings.
Education & Training
Methodist Hospital (Houston)Residency, Neurology, 2011 - 2015
University of Texas Medical Branch School of MedicineClass of 2011
Certifications & Licensure
TX State Medical License 2015 - 2025
American Board of Psychiatry and Neurology Neurology- American Board of Psychiatry and Neurology Neuromuscular Medicine
Clinical Trials
- T-regulatory Cells in ALS Start of enrollment: 2019 Aug 07
Publications & Presentations
PubMed
- Barriers to Tofersen Therapy for Variant SOD1-Mediated ALS.Stanley H Appel, Jason R Thonhoff
JAMA Neurology. 2024-12-01 - 3 citationsA phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic...Jason R Thonhoff, David R Beers, Weihua Zhao, Alireza Faridar, Aaron Thome
Frontiers in Neurology. 2024-01-01 - 16 citationsCombined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral Sclerosis.Jason R Thonhoff, James D Berry, Eric A Macklin, David R Beers, Patricia A Mendoza
Neurology(R) Neuroimmunology & Neuroinflammation. 2022-11-01
Press Mentions
Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)March 21st, 2023- ALS Patients' Own Cells May Provide a Safe Pathway to Slow or Halt ProgressionOctober 7th, 2022
- When Spinal Fluid from ALS Patients Was Put into Mice, the Mice Got Weak. An Unlikely Protein Could Be the CulpritAugust 22nd, 2022
- Join now to see all
Grant Support
- Combined Stem Cell And Anti-Oxidative Therapy For ALSNational Institute Of Neurological Disorders And Stroke2007–2010
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
